(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05420 A1

(51) International Patent Classification[7]: A61K 38/04, 38/06, 38/07, C07K 5/00, 5/08, 5/10

(21) International Application Number: PCT/US00/19496

(22) International Filing Date: 14 July 2000 (14.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/144,539 16 July 1999 (16.07.1999) US

(71) Applicant *(for all designated States except US)*: HISTATEK, LLC [US/US]; 37 St. Germain Avenue, San Francisco, CA 94114 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: CLARGETT, James [US/US]; P.O. Box 914, Snohomish, WA 98290 (US).

(74) Agents: NEUNER, George, W. et al.; Dike, Bronstein, Roberts & Cushman, Intellectual Property Group, Edwards & Angell, LLP, 130 Water Street, Boston, MA 02109 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/05420 A1

(54) Title: SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IGE

(57) Abstract: A method for downregulating IgE levels is described. The method involves administering to a patient an IgE downregulating effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.